期刊文献+

不同双膦酸盐类药物在骨代谢的实验研究 被引量:9

The comparison of different bisphosphonates in bone metabolism using animal models
下载PDF
导出
摘要 目的合理选择双膦酸盐类药物为临床治疗骨质疏松提供依据。方法通过实验兔肌肉注射地塞米松磷酸钠注射液方法制作骨质疏松动物模型,并对骨质疏松模型分别进行"99Tc-MDP"、"阿仑膦酸钠"和"博宁"治疗后的疗效研究,实验室分析指标:病理骨组织学、骨密度、生物力学试验、骨形态计量、放射性"99mTc-MDP"骨骼显像ROI比值、X线、CT摄片及血清骨碱性磷酸酶(BALP)、骨钙素(BGP)。并与骨质疏松模型对照组比较,评判各组间的差异。采用SPSS13.0软件进行统计学处理分析。结果经肌肉注射盐酸地塞米松方法制作骨质疏松模型试验,在病理骨组织学、骨密度、生物力学试验、BGP等指标均出现骨质疏松征象,证实骨质疏松模型成立。在骨质疏松的基础上,经"99Tc-MDP"、"阿仑膦酸钠"和"博宁"各治疗组的治疗,均有较明显的改善,但存在不同程度的差异,改善程度依次为"99Tc-MDP"治疗组、"阿仑膦酸钠"治疗组和"博宁"治疗组。结论不同的双膦酸盐类药物在骨组织生理代谢不一样,所产生的疗效也不同。"阿仑膦酸钠"是在"博宁"的基础上研制的新一代治疗骨质疏松症的双膦酸盐,所以抑制骨吸收优于"博宁"。而"99Tc-MDP"可能对骨组织还具有免疫调节价值。对不同的双膦酸盐在骨组织生理代谢作用的治疗价值将可为临床治疗方向提供依据。 Objective To validate the optimal bisphosphonate in the treatment of osteoporosis using animal models and provide evidence for more appropriate clinical uses of bisphosphonates.Me thod First we established osteoporotic rabbit models by injecting dexamethasone sodium phosphate intramuscularly.And then the animal models were divided into four different groups and treated with99Tc-MDP,alendronate and pamironate disodium respectively.The effects of the three different drugs were investigated by comparing with the control group and by analyzing laboratory test,bone histology,bone density,biomechanical test,ROI ratio of99mTc-MDP bone scintigraphy,X ray,CT tomography,BALP as well as BGP.The statistical analysis was carried out using SPSS13.0.Re sult Although all the three methods had relieved the osteoporosis in our experimental groups,99Tc-MDP is the most effective therapy when compared with alendronate or pamironate disodium.Conclusion Depending on different mechanisms in bone metabolism,the effects of bisphosphonates vary among different therapies.Alendronate is the newly developed bisphosphonate based on pamironate disodium,as a result,it behaves much better when inhibiting bone absorbing in treating osteoporosis.In addition,99Tc-MDP may exerting therapeutic effects through immunization routes.Our research will provide value for more appropriate treatment of osteoporosis.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2016年第3期304-308,共5页 Chinese Journal of Osteoporosis
关键词 双膦酸盐 骨质疏松 动物模型 治疗 Bisphosphonate Osteoporosis Animal models Treatment
  • 相关文献

参考文献10

二级参考文献61

  • 1孙建琴,詹国英,孙晓红.维生素D与骨质疏松及其骨折的防治研究[J].中国骨质疏松杂志,1998,4(4):78-83. 被引量:9
  • 2高克加,叶智卫,王建华,梅小刚,李伟.锝-99-亚甲基二膦酸钠与中药速效骨伤愈合剂治疗骨质疏松动物实验研究[J].上海医学,2006,29(8):569-571. 被引量:3
  • 3李茂良.“云克”系列药品的特点和治疗机理研讨.全国核素治疗研讨会论文集[M].,1999.16-30.
  • 4Lauriten JB. Prevention withhipprotectos Bionedical aspects in falls and hipfractures. Nord Med, 1996,11 (10) :340-343.
  • 5Rogers M, Gordon S, Benford L, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000, 88 (suppl) :296-12978.
  • 6Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporsis: a 3-year randomized placebo-conteclled clinical trial with a 2-year oper exrension. J Bone Miner Res ,2002,17 ( 6 ) : 1057-1064.
  • 7Irina M, LiLian IP, Cecilia LS, et al. Extrncellar sigoal-kinase and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res, 2001,16: 2050-2056.
  • 8Luckman SP, Hughs DE, Coxon FP, et al. Netrogen-containing bisphosphonates inhabit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res,1998, 13: 1668-1678.
  • 9Fisher JE, Rogers MJ, Hslasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad ,Sci USA, 1999
  • 10Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitroge-containing bisphosphonates. J Pharmacol Exp Ther, 2001, 296: 235-242.

共引文献92

同被引文献75

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部